ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 68 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,399,864 | -15.7% | 38,974,185 | 0.0% | 0.36% | -12.9% |
| Q2 2023 | $36,051,121 | -15.1% | 38,974,185 | 0.0% | 0.42% | -27.4% |
| Q1 2023 | $42,481,862 | -25.3% | 38,974,185 | 0.0% | 0.58% | -46.9% |
| Q4 2022 | $56,902,310 | +35.8% | 38,974,185 | 0.0% | 1.09% | +35.6% |
| Q3 2022 | $41,897,000 | -36.8% | 38,974,185 | 0.0% | 0.80% | -46.7% |
| Q2 2022 | $66,256,000 | -17.5% | 38,974,185 | 0.0% | 1.50% | +55.8% |
| Q1 2022 | $80,287,000 | -45.1% | 38,974,185 | 0.0% | 0.96% | -40.7% |
| Q4 2021 | $146,153,000 | -27.5% | 38,974,185 | 0.0% | 1.63% | -29.0% |
| Q3 2021 | $201,497,000 | +21.4% | 38,974,185 | 0.0% | 2.29% | +26.4% |
| Q2 2021 | $166,030,000 | -19.8% | 38,974,185 | 0.0% | 1.81% | -24.1% |
| Q1 2021 | $206,953,000 | -1.5% | 38,974,185 | 0.0% | 2.39% | +5.2% |
| Q4 2020 | $210,071,000 | -32.5% | 38,974,185 | 0.0% | 2.27% | -45.0% |
| Q3 2020 | $311,014,000 | -20.3% | 38,974,185 | 0.0% | 4.13% | -32.0% |
| Q2 2020 | $390,132,000 | +316.6% | 38,974,185 | +13.2% | 6.08% | +154.1% |
| Q1 2020 | $93,646,000 | +178.7% | 34,428,730 | +23.0% | 2.39% | +234.8% |
| Q4 2019 | $33,600,000 | -20.5% | 28,000,000 | 0.0% | 0.72% | -31.4% |
| Q3 2019 | $42,280,000 | -62.4% | 28,000,000 | 0.0% | 1.04% | -49.9% |
| Q2 2019 | $112,560,000 | -6.5% | 28,000,000 | 0.0% | 2.08% | -35.2% |
| Q1 2019 | $120,400,000 | -22.9% | 28,000,000 | +3.1% | 3.21% | -37.9% |
| Q4 2018 | $156,107,000 | -43.5% | 27,149,000 | +33.3% | 5.17% | -24.2% |
| Q3 2018 | $276,109,000 | +65.2% | 20,362,011 | +44.6% | 6.82% | +43.6% |
| Q2 2018 | $167,171,000 | +7.2% | 14,083,511 | +1.5% | 4.75% | -12.4% |
| Q1 2018 | $155,895,000 | +91.1% | 13,882,011 | +13.7% | 5.42% | +86.2% |
| Q4 2017 | $81,586,000 | -17.3% | 12,213,511 | +1.4% | 2.91% | -7.6% |
| Q3 2017 | $98,636,000 | +152.7% | 12,043,511 | +38.6% | 3.15% | +137.9% |
| Q2 2017 | $39,027,000 | – | 8,692,083 | – | 1.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |